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ABSTRACT
Diseases affecting the retina, such as Age-related Macular Degeneration (AMD) and
Retinitis Pigmentosa (RP), result in the degeneration of the photoreceptor cells and can
ultimately lead to blindness in patients. There is currently no cure for AMD or RP, and only a few
methods exist for slowing the progression of these diseases. Although there has been much
recent headway in cell replacement therapy to restore vision loss, a number of challenges still
remain. More specifically, there is a need for the development of a device that can deliver a large
number of cells to the posterior segment of the eye, while promoting cell survival,
differentiation and integration into the retina following transplantation. This research focuses
on designing a device to meet these demands and improve the vision of those afflicted with
blinding diseases.
The specific hypothesis behind the proposed research is that a MEMS-based strategy to
engineer a device can provide precisely defined spatial and chemical cues to influence retinal
progenitor cells (RPCs) attachment, promote differentiation, and provide physical guidance in a
more normal anatomical organization for their integration as neurosensory retina after
transplantation to the subretinal space. Therefore, the specific aims of this research are to
design, fabricate, and evaluate in vitro a novel ultrathin 3-D device made of polycaprolactone
(PCL) for retinal cell replacement synthesized by the stacking, aligning, and bonding of three
uniquely designed layers. Photolithography, standard replica molding, and soft lithography
techniques are used to fabricate the device elements.
The 3-D device is designed with a defined cage structure to encapsulate a large number
of cells. Another layer of the design allows for unidirectional cell migration out of one end into
the subretinal space with the aid of contact guidance ridges. The third design layer allows for
nutrient infiltration from the retinal pigment epithelium into the cell cages. The ultimate goal is
to provide an environment compatible with the normal retinal tissue and conducive to the
formation of functional synapses under the appropriate conditions, thereby restoring proper
vision. With demonstration of efficacy and cell retention in vitro, the scaffold has the potential to
reverse retinal degeneration due to disease or trauma and improve retinal function and
integrity in vivo.
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Chapter 1: Introduction
1.1An Introduction to Regenerative Therapy
The solution to some of the most pressing medical challenges may lie in the
promise of regenerative medicine. New strategies to regenerate tissues and organs
for the treatment of injuries and diseases have the potential to resolve the
worldwide problem of organ shortages. Though many elements of the human body
such as skin and blood are naturally regenerative, diseases and serious injuries can
be so damaging that they result in complete loss of functionality without the
potential for regeneration. Recent figures claim that an estimated 97,000 people in
the United States awaited life-saving organ transplants in 2007'. Given that there
were approximately 28,000 transplants total performed in the United States that
year2 , it is clear that the demand for organs cannot be met at the current donation
rate. Of all those who do not receive organs, 17 of them die each day while waiting.
Furthermore, the wait for an organ is three to five years on average, as each day the
wait list grows five times faster than the donation list. 1
To meet the demand for tissues and organs in an efficient and safe manner,
strategies such as regenerative medicine may be the solution. Regenerative therapy
is a multidisciplinary effort- it requires integration of concepts from biology,
chemistry, materials science, engineering, and medicine, among others. The
underlying strategy is consistent throughout all applications of the therapy. Cells
from a biopsy are used to form a monolayer cell culture and subsequently an
expanded line of cells. These cells are then cultured on a 2D or 3-D polymeric
scaffold for the generation of a graft. The graft is then transplanted to the relevant
site in the host tissue or organ to induce regeneration. With the appropriate host
environment and therapeutic signals, the tissue regenerates to restore function and
is nearly indistinguishable from native tissue.
In theory, the optimized combination of biomaterials and polymers, stem cell
or progenitor cell populations, and growth factors will induce generation of tissues
and organs. There has been much recent headway in the engineering of skin,
-W1 M 1 - - --: rr= -L-, -t - . .. . . . . . . - 1 l l .' W .... .... - - --- --.
cartilage, liver, bone, and heart valves, among other tissues. Though regenerative
medicine is fairly straightforward in principle, it can be very challenging to
implement in practice. Optimization of the scaffold materials, cells, and therapeutic
agents require extensive in vitro and in vivo testing before the possibility of
transplantation into humans.
1.2 Biology of the Retina
The retina is the multi-layered sensory tissue that lines the back of the eye, as
shown in Figure 1-1. The thickness of the retina ranges from .1 mm to .56 mm
depending on the region.3 The retina is composed of approximately seven distinct
layers, as shown in the figure. The photoreceptors in the retina capture light rays
and convert them to electrical impulses that travel along the optic nerve. The
impulses are then converted to images in the brain. The photoreceptors, namely the
rods and cones, are central to the maintenance of healthy vision. There are
approximately 6 million cones in the macula, or the center of the retina responsible
for central vision. The cones allow for detection of color. The retina contains 125
million rods, which are responsible for night vision, spread throughout the
periphery of the retina.4
Optic Nerve Fibers
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FIGURE 1-1: Schematic of the eye and the retina. 5,6
Source of eye diagram: American Academy of Ophthalmology
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In designing a device for stem cell delivery to the posterior segment of the
retina, consideration of the retinal microenvironment is essential. The scaffold must
be very thin, given that the retina itself is only 100 to 560 iim thick. A thinner
scaffold will be less disruptive to the host tissue anatomy and less invasive on the
surrounding structures. The subretinal space is artificially created during the
transplant procedure. Therefore, thick implants greater than 30 iim will induce
trauma during transplantation and ultimately interfere with the normal functioning
of other layers of the retina. In addition, it is important to appreciate that the retina
is a polarized tissue that lies on the retinal pigment epithelium on one end. The
other end of the retina is the optic nerve fiber layer that absorbs the incident light.
Furthermore, in order to maintain the mechanical uniformity and stability of the
retina during the regenerative process, the scaffold should exhibit mechanical
properties comparable to that of the retina. For example, the retina's elastic
modulus is 0.1 MPa and maximum strain at failure is 83%. 7 However, the scaffold
ultimately degrades, and so the retinal regenerative therapy does not hinge on the
mechanical properties of the device.
1.3 Retinal Diseases
Retinal diseases vary widely in terms of frequency, symptoms, diagnosis, and
treatment. Some of the most common retinal diseases include Retinal Detachment,
Retinal Tears, Diabetic Retinopathy, Retinal Vascular Occlusion, and Macular Holes,
among others. Two retinal diseases that ultimately lead to blindness and for which
current treatment options are limited are Age-related Macular Degeneration (AMD),
the most common cause of legal blindness among older Americans, and Retinitis
Pigmentosa (RP), a rarer, inherited disease. These diseases are caused by
degeneration of the retina over time. For this reason, they are appropriate targets
for strategies of retinal regenerative therapy.
1.3.1 Age-Related Macular Degeneration
AMD is the leading cause of blindness in Americans age 65 and older.8 More
than 1.75 million people in the U.S. have AMD, and this number is expected to reach
almost 3 million by 2020 due to the increasing size of the elderly population.9 The
disease is the result of genetic and environmental factors, and it gradually results in
the loss of sharp, central vision with age, as shown in Figure 1-2.
Normal Vision Vision with AMD
FIGURE 1-2: Deterioration of vision associated with AMD.10
Source: National Eye Institute, National Institutes of Health
The loss of central vision occurs due to degeneration of the macula, the
center of the retina that allows one to see detail, as shown in Figure 1-3. Women are
slightly more likely to develop AMD than men. A common symptom of AMD is the
presence of drusen, or yellow deposits under the retina around the macular region.
Though AMD does not result in pain, the effects on vision can be very detrimental to
the quality of life.
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FIGURE 1-3: Pathology associated with AMD.11
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There are two types of AMD, dry (non-neovascular) and wet (neovascular).
90% of patients with AMD suffer from the dry form of the disease, which involves
the slow and gradual shrinkage of the retina and degeneration of retinal layers. The
patients suffer severe visual handicaps due to the gradual loss of central vision. The
remaining 10% of patients with AMD have the wet form of the disease. This type is
the more serious form and leads to 90% of the blindness associated with the
disease. In wet AMD, new blood vessels grow under the retina and leak blood and
fluid. This fluid permanently damages the light-sensitive retinal cells and results in
central vision loss. 12 Factors associated with AMD are aging, obesity, heredity,
hypertension, smoking, lighter eye color, and drug side effects. 13
There is currently no cure for AMD, and no way to completely stop its
development. However, there are some treatments that may slow the progression of
disease. There is no FDA-approved treatment for dry AMD, but Vitamins A, C, E, and
other nutritional supplements, as well as sunglasses with UV protection, may slow
its progression. Treatments for wet AMD that are aimed at stopping abnormal blood
vessel growth include FDA-approved drugs Lucentis, Macugen, Avastin, and
Visudyne used with Photodynamic Therapy.
1.3.2 Retinitis Pigmentosa
Retinitis pigmentosa (RP) is a rare, inherited disease that affects
approximately 80,000 people in the United States, or 1 in 3700.14 In RP, the rods
that are responsible for night vision in dim light gradually deteriorate, making night
vision poor. As shown in Figure 1-4, peripheral vision also deteriorates. Only a small
area of central vision, or tunnel vision, remains as the disease progresses ultimately
towards blindness.
Similar to dry AMD, there are currently no treatments available for RP,
although supplements of Vitamin A may delay the vision loss.15 Individuals with RP
might also consider using low vision devices that help to magnify and illuminate
objects. Clearly, there is a need for treatment of retinal diseases that deteriorate
photoreceptor cells and result in blindness.
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Vision with RP
FIGURE 1-4: Deterioration of vision associated with RP.16
Source: National Eye Institute, National Institutes of Health
Although no visually beneficial treatments exist for AMD and RP, a number of
approaches are under investigation, including the development of cell-scaffold
composites for tissue engineering. Retinal pigment epithelium (RPE) transplants
and retinal prosthesis are also being developed to enhance retinal function in
patients suffering from retinal degenerative disease.
1.4 Current Status of Retinal Progenitor Cell Grafting
Photoreceptor loss and retinal degeneration are currently untreatable
conditions. However, there are several therapies in development that employ a
variety of strategies. These therapies include delivery of stem or progenitor cells to
the outer retina, design of bulk scaffolds for stem cell delivery, and design of MEMS-
based and nanostructured 2-D scaffolds.
1.4.1 Injection-based Cell Delivery
To successfully graft retinal progenitor cells (RPCs) to the retina requires
overcoming challenges of delivery methods, cell survival, migration, and
differentiation, among other obstacles. Some of the earlier approaches for retinal
tissue engineering consisted of the bolus injection of a cell suspension into the
subretinal space. 17 However, delivering cell suspensions into the vitreous cavity or
subretinal space by injection does not lead to high levels of cell survival due to the
Normal Vision
shear forces involved in the process. Furthermore, the cells create a disorganized
array and often localize to the wrong region of the retina.
1.4.2 Scaffold-based Cell Delivery
Subsequent research found that delivering the cells on a scaffold enhances
cell survival and differentiation ability. A cornerstone of tissue engineering is the
design of scaffolds that stem cells can be cultured on and the subsequent delivery of
the cell-scaffold composite to the pertinent site of degeneration. In the case of
retinal tissue engineering, stem cells or retinal progenitor cells (RPCs) are cultured
on scaffolds and transplanted to the subretinal space. It is theorized that this
process promotes cell survival, integration, and differentiation. However, the
scaffold must be biocompatible and mechanically compatible with the retina in
order for use in transplantation. Many recent advances in materials processing and
fabrication allow for precise control of scaffold design and material parameters in
order to mimic native tissue microenvironments. Regulation of properties such as
topography, adhesion molecules, and soluble factors allows better control of cell
behavior and host tissue response.
1.4.2.1 Irregular Bulk Scaffolds
Surface modifications can be utilized to control responses at the biological
interface of synthetic or natural biomaterials upon implantation. Changes in
architecture and surface topography can result in a material that closely mimics
native tissue responses. For example, one study evaluated degradable PLA/PLGA
scaffolds for their effects on the survival and differentiation of retinal progenitor
cells. 18 The scaffolds were fabricated by phase-inversion casting and solid-liquid
phase separation to have heterogeneous size pores ranging from 50 to 200 lIm.
Delivering RPCs on a PLA/PLGA composite graft .3 mm in thickness induced
morphological changes in RPCs that were evidence of differentiation. The cells
exhibited a high degree of polarization consistent with photoreceptor cells as well
as an increase in cell survival. Attachment of RPCs to the scaffold was associated
--Wag Now"W"WOM
with down-regulation of immature cell markers and up-regulation of mature cell
markers.
1.4.2.2 MEMS-based 2-D Scaffolds
The concept of cell delivery via a scaffold was advanced further by
integrating computer-aided design and microfabrication processing technology to
control scaffold architecture, including parameters such as porosity and topography.
MEMS technology allows for more precise control of scaffold features and more
uniform, reproducible pore size and shape. The micropatterned substrates can be
designed to encourage cell attachment, migration, and differentiation into the
appropriate phenotype. Furthermore, the microfabrication processing allows for a
scaffold design closest to native retinal anatomy and increases the potential for
reformation of photoreceptor synapses. This technology has been applied to a
variety of polymers to fabricate scaffolds for RPC grafting.
One study evaluated the effect of non-degradable poly(methyl mathacrylate)
(PMMA) scaffolds 6 [im thin on the survival, migration, and differentiation of RPCs.19
It showed that porous micropatterned PMMA scaffolds demonstrate enhanced RPC
adhesion and cell migration into the host retina as compared to smooth, non-porous
scaffolds. Photolithography and reactive ion etching were used to make an 11 [pm
pore diameter with 63 ptm in between pores. The study showed that even though
porous and non-porous scaffold exhibit biocompatibility, cell survival, and
adherence, the porous scaffold allows for better attachment of cells up to four weeks
after transplantation to the subretinal space. Furthermore, the pores provided a
stimulus from migration into the native retinal layers. The non-porous scaffolds had
limited retention of RPCs.
In another example of precisely designed pore structures, Neeley et al.
fabricated a PGS scaffold for retinal progenitor cell grafting using standard
microfabrication and replica molding techniques. 20 The scaffold, 45 p.m in thickness,
consisted of a uniform porous structure with 50 [pm pores, approximately the
thickness of the scaffold. It exhibited mechanical properties well suited for the
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retina, including Young's modulus (1.66 ± 0.23MPa) and maximum elongation at
failure of 113 + 22%. RPCs strongly adhered to the scaffold and proliferated.
Immunohistochemistry revealed the presence of some mature cell markers at
various time points after cell seeding, indicating cell differentiation. This study
further demonstrated the ability of RPCs to attach to polymer scaffolds in the
subretinal transplantation process as well as the potential of using a porous design.
The cells are able to attach to the scaffold via cell anchorage mechanisms to the
pores and embedment inside the pores. This also allows other surrounding RPCs to
attach to the scaffold via cell-cell contact.
1.4.2.3 Nanostructured 2-D Scaffolds
Engineered nano-scale features on scaffolds made of fibrous or porous
materials also have the ability to elicit a cell response. For example, nanowires have
shown biocompatibility, cell adhesion and migration, and tissue organization. In one
study, RPCs were cultured on smooth poly(e-caprolactone) (PCL) and on short and
long biodegradable, thin film nanowire PCL scaffolds. 21 PCL nanowires and
nanofibers with average diameter of 150-100 ptm, length of 2.5 lm or 27.5 [lm, and a
spacing of 20 [lm, were fabricated using a hot melt templating approach. Not only
are the nanowire scaffolds very thin, but PCL is also very permeable and has a
predictable degradation rate well-suited for subretinal implantation. RPCs were
seeded on these constructs, and the scaffolds were then transplanted into the
subretinal space of mice for observation of RPC integration, differentiation, and
long-term survival.
The RPCs seeded on the smooth PCL randomly adhered to the surface and
remained spheroid in shape. By day 3, there was no alignment to specific surface
regions, presumably due to the lack of structural cues, though there were cell-cell
contacts. The long PCL nanofibers folded over to form microstructured ridges that
the RPCs adhered to while remaining spheroid. The RPCs that localized to the
formed micropits extended outwards to maintain contact with the ridges. Because
the short, densely-packed nanowires reduced the surface area that cells could attach
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too, RPCs attached individually to the tips of nanowire groups. On day 3, the cells
appeared to have formed cell-to-cell fan-like processes thereby creating contacts.
Futhermore, after day 7 the cells had formed a dense monlayer on the nanowire
surfaces with processes connecting the cells. The RPCs proliferated strongly and
expressed mature retinal proteins in response to the interactions with the nanowire
scaffold. The cells also demonstrated significant migration ability. This study builds
on other findings that RPCs have the potential to respond to the structural stimulus
of micro- or nano-patterned surfaces. This can be used advantageously to direct the
differentiation of cells. The cell-scaffold composite grafts improve the survivability
and differentiation of the transplanted cells and have applications in retinal disease
treatment.
1.4.3 Disadvantages of Current Strategies
There are a number of disadvantages of the methods described above,
warranting the need for further development of practical solutions for stem cell
delivery to the subretinal space. As described above, stem cell bolus injections have
too many shear forces in the delivery process, thereby diminishing cell survival and
proliferation. Thus, scaffolds are a necessary element of retinal regenerative
therapy, but they should be able to carry a large number of cells and have an
organized, defined structure. Bulk, porous scaffolds of various size pores can carry a
large number of cells, but the cells are not able to migrate out of the scaffold easily.
Cells are also distant from each other as well as from the host environment. These
scaffolds are thick and may be disruptive to the native retinal tissue. Furthermore,
they are not reproducible in design. Thin film 2-D platforms allow for enhanced cell
migration out of the scaffold, but they are only able to carry a limited layer of cells.
In addition, this layer can be sheared off relatively easily during the transplantation
process. Clearly, there is a need for a precise, uniform device design that can hold a
large number of cells and allow for cell survival and migration.
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1.5 Biomaterials
1.5.1 Role of Biomaterials in Regenerative Therapy
Biomaterials play a fundamental role in the fields of regenerative medicine
and tissue engineering. Interactions of cells, which are either transplanted in the
scaffold or already in the host tissue, with the scaffold material determine how the
cells function and respond upon transplantation. Biomaterials are also able to direct
cell-cell interactions and guide cell responses. Both synthetic and natural polymers
have distinct merit in applications, as do hybrid polymers. Furthermore, the scaffold
material serves to strengthen the structural integrity of the defect site during the
period of regeneration. It prevents infiltration or collapse of surrounding tissue into
the defect site. The biocompatibility and mechanical compatibility of the scaffold
material are central to the efficacy of a device. The 2-D and 3-D patterning of
biomaterials can achieve a biomimetic model of complex tissue architecture. Finally,
the biomaterial's permeability and degradation rate directly impact the time course
of tissue regeneration.
1.5.2 Existing Materials in Use
Despite advances in the field of biomaterials science and development of a
variety of polymers, it is difficult to find a material with optimal mechanical
properties for retinal tissue engineering and one that can be fabricated at the
desired thinness for use in the retina. For example, though PLGA is biodegradable, it
does not have the best material properties for a retinal implant. It has rigid and firm
mechanical properties, exhibits bulk degradation, and has limited biocompatibility
in some cases. 22
Poly(glycerol sebacate) (PGS) is a tough biodegradable elastomeric polymer
that has mechanical properties well-suited for tissue applications. It was first
synthesized in 2002 by Y.Wang et al. based on glycerol and sebacic acid. 23 The
elastomer forms a covalently crosslinked, three-dimensional network of random
coils. It shows good biocompatibility, is relatively inexpensive to synthesize, and is
fairly flexible. This evaluation found that PGS degrades primarily by surface erosion
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in vivo, preserving geometry and retaining mechanical strength as mass decreases. 24
PGS has been studied as a material for tissue engineering scaffolds for applications
such as cardiac, soft, and vascular tissue engineering. However, curing PGS to the
desired thinness required for this retinal application and with facilitated
delamination is challenging.
1.5.3 Suitability of Polycaprolactone (PCL) for Retinal Applications
Previous studies have shown that RPCs can be cultured with PCL nanowire
substrates.25 These scaffolds were biologically compatible with RPCs given the
indications of cell adhesion and proliferation. Furthermore, the thin film structure of
the PCL offered two important advantages for transplantation to the subretinal
space. First, the thinness allows the scaffold to be placed with minimal disturbance
to the host retinal tissue. Secondly, PCL is highly permeable and allows for
physiologically significant molecules such as nutrients to pass through the scaffold.
In addition, the scaffold has a predictable degradation rate; the process occurs
gradually at the scaffold surface. As it degrades, there are no increases in local
acidity as seen in bulk degradation of higher molecular weight polymers such as
PLGA.26 PCL is a degradable polyester with a low melting point around 60'C. The
features of PCL are conducive to the efficacy of stem cell delivery to the subretinal
space via a microfabricated scaffold.
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Chapter 2: Specific Aims and Scaffold Design
2.1 Scaffold Design
Given the shortcomings of current retinal progenitor cell grafting techniques
described above, there is a need for a retinal tissue engineering scaffold that meets
the following criteria:
- Measures approximately 30rim in thickness to prevent harm to the native
retina.
- Delivers and supports survival of a maximum number of cells during
transplantation.
- Encourages migration of cells out of the scaffold.
- Prevents infiltration of surrounding cells and tissue.
- Has mechanical properties compatible with the retinal tissue and serves to
reinforce retinal tissue architecture.
The proposed scaffold structure in Figure 2-1 is designed to accomplish these goals.
Cells
migrate out
Nutrients
diffuse in
FIGURE 2-1: Cross-section view of proposed scaffold design
to show both interior and exterior.
In Figure 2-1, a 3 cage x 3 cage scaffold design is shown for clarity. A fabricated
scaffold construct is a circle measuring 5mm in diameter, has approximately 300
cages to hold cells, and can hold approximately 2.6x10 4 cells in total. The scaffold
r
size can also be increased or decreased depending on the size of the biopsy punch
used for fabrication. Figure 2-2 depicts the relative location of the device in the
retina upon transplantation.
Cells Out Nutrients In
Light I
Implanted Pigmnnt
Device Epi#elium
FIGURE 2-2: Depicts location of the device in the retina post-transplantation. 27
As shown in Figure 2-2, the device is inserted between the photoreceptor
neuroretina and the retinal pigment epithelium via an incision by the surgeon
through the front or the back of the eye. Figure 2-3 depicts the cross-section of the
scaffold with the dimensions of an individual cage for cell encapsulation. The
thickness of the entire scaffold is approximately 30 tm, which is thin enough to
prevent serious damage to the host retina. Notable design measurements are the
cage diameter of 216 rm, the nutrient infiltration pores with a diameter of 10 tm,
and cell migration pores with a diameter of 72 pim.
L
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FIGURE 2-3: Cross-section of the scaffold with dimensions of an
individual cage for cell encapsulation (all units in gm). Each cage
can hold approximately 88 tightly packed cells.
There are several components of the rationale for the scaffold design, outlined
below.
Ultrathin scaffold: The 30 gm thickness will increase the chances of RPCs receiving
copious nutrients and decrease the chance of the scaffold disturbing the host retinal
tissue.
Nutrient Infiltration: The condition that cells should be within 20011m of a nutrient
source28 will be met with this scaffold design due to the many channels for nutrient
delivery.
Delivery of a large number of cells to subretinal space: There is a need for a scaffold
that can encapsulate and deliver a large number of cells, unlike current designs in
which one layer of cells is seeded onto a scaffold and can be easily sheared off
during transplantation. The proposed scaffold design will be able to hold a large
number of cells upon transplantation to the subretinal space. In addition, the cages
will provide a protective environment to prevent damage to the cells. Given a
scaffold cage diameter is 216 pm, the cell density in each cage will be large enough
to populate the subretinal space yet not too large so as to inhibit the cells from
proliferating. Each cage is capable of holding 88 tightly packed cells by volume
assuming cells are approximately spherical with a radius of 10 pm. A circular
216
scaffold measuring 5 mm in diameter has approximately 300 cages and can
encapsulate approximately 2.6x10 4 cells total.
Unidirectional cell migration out of the scaffold: The device will not only allow the
cells to migrate out of the scaffold but will also do so in a unidirectional manner. Due
to the larger pore size on one end (72 [m) and smaller pore size on the other end
(10 km), the RPCs will selectively migrate unidirectionally towards the
photorecepters in the retina out of the larger pore because they are too large to
travel across the smaller pores. Nutrients will diffuse in from the pigment
epithelium through the smaller pores, which are 10 [im in diameter. This will allow
for nutrient delivery into the channels while preventing cell migration out of the
channels towards the pigment epithelium.
Contact guidance cues: The larger 72 pam pores for cell migration are designed with
hexagonal ridges to serve as built-in contact guidance cues that promote the
attachment and migration of cells. Contact guidance cues with ridge-groove
geometries have been demonstrated to enhance cell orientation and morphology in
previous literature.29 The shape of the posts on the silicon wafer negative mold that
is used to synthesize the pores for cell migration out of the scaffold is shown in
Figure 2-4.
Figure 2-4: Shape of posts on silicon wafer mold that is used to
synthesize cell migration pores with built-in contact guidance
hexagonal ridges, shown in L-Edit design software.
The hexagonally ridged geometry in the PCL scaffold will line the 10 im thick cell
escape pores and provide contact guidance. Not only will this encourage the cells to
migrate out of the scaffold, but it will also do so unidirectionally since these ridges
are only present on one end of the scaffold.
Open to the retina on both sides: The scaffold is open to the retina on both sides. This
will allow for endogenous nutrients and regulators to infiltrate the scaffold. In
addition, it will allow for better integration of the scaffold into the subretinal space.
Lastly, this feature makes the retinal regenerative process less dependent on the
degradation rate of the PCL polymer because the tissue can already communicate
from one end to the other.
Large Surface Area: The large surface area created by the cages allows for more cell
adhesion and migration ability.
Potentialfor Drug delivery: This design can be readily modified to incorporate
growth factors and other small molecules. This would allow the RPCs to begin
differentiation prior to their migration out of the scaffold. By the time the cell
reaches the photoreceptor layer, it will have received cues to differentiate into a
photoreceptor cell and localize to that region of the retina. This will diminish the
likelihood of the cell migrating elsewhere in the retina or differentiating into a
different cell in the RPC lineage.
2.2 Advantages of the Scaffold Design
The scaffold design allows for delivery of a large number of cells contained in
an organized, 3-D MEMS-based scaffold. The micropatterned uniform and precise
architecture increases the anatomical organization of the device and increases the
chances of developing functional photoreceptors and forming synapses. The scaffold
design also enhances protection of the cells during the transplantation procedure. It
is biodegradable and biocompatible, facilitating its transition to in vivo testing and
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human applications. The scaffold is open to the retina on both sides, allowing for
communication, nutrient infiltration, and integration. The cells are centrally held,
while channels on one side allow nutrient delivery from the retinal pigment
epithelium and channels on the other side allow for RPC migration into the
photoreceptor layer of the retina. The channels for cell migration have built-in
contact guidance cues via hexagonally ridged pores in order to encourage cell
migration out of the scaffold into the photoreceptor layer. In addition, this allows
the cells to respond to the host environment without dependence on the
degradation rate of the polymer.
Furthermore, scaffold parameters can be simply altered during fabrication to
increase the number of cells the device can load. The channels that open to the
retina can also be altered in terms of size and shape. The unidirectional migration of
the cells is due to the sizing of the channels; the channel size is large enough for cells
to migrate through on only one side of the cages. The thinness of the entire scaffold
limits the invasiveness of the device on the host retinal tissue. Furthermore, due to
the layer-by-layer construction of the device, each layer can be modified and
tailored to meet specific topological, chemical, or drug delivery needs. Each layer
can also have a different topography on either side of it for tailored interaction with
the transplanted or host cells. Finally, the method is cost-effective and highly
reproducible as a result of the photolithography and soft lithography techniques
employed.
There are several novel features of the device that distinguish it from other
retinal therapies in development. First is the design of an architectural chamber for
encapsulation of cells and promotion of retinal differentiation. Second is the thin
film three-dimensional nature of the scaffold that allows for communication of the
interior of the device to the exterior on both sides. In addition, this decouples the
cell integration and differentiation from the material degradation properties.
Finally, the scaffold affords the opportunity to precisely control physiological,
chemical, or structural features and enhance RPC culture.
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Chapter 3: Fabrication of Polycaprolactone Thin
Film 3-D Scaffolds
3.1 Introduction to MEMS
MEMS are micro-electro-mechanical systems and technology at the micro-
level. MEMS technology can be implemented using a variety of materials and
processing techniques. Materials include silicon, polymers, and metals. Processes
include deposition, photolithography, etching, and micro-machining. Three-
dimensional thin film scaffolds with features at the micron scale are fabricated using
MEMS based microfabrication strategies in order to allow for precise control of the
scaffold structure. Specific processes that will be used to fabricate the device
elements include photolithography, standard replica molding, and soft lithography
techniques. The overall fabrication process includes the following procedures: mask
design using L-Edit software, standard SU-8 photolithography, standard replica
molding, soft lithography with PDMS, polycaprolactone (PCL) thin film fabrication,
and pressure bonding of thin films.
3.2 Materials and Methods
3.2.1 Mask design using L-Edit Software
Masks for the three layers of the scaffold structure are designed using L-Edit
Software. The L-Edit designs for the three individual scaffold layers are shown in
Figure 3-1.• * ........-..
gO000000*0* * * ****0
OOOOOOOOOOOO0
0000000000** ,00
r
Feature layouts prepared in microfabrication design software (L-Edit) are printed
onto transparent flexible photomasks using a laser printer with up to 20,000 dpi
resolution (Art/CAD Services in photoplotting).
3.2.2 Standard SU-8 Photolithography
Standard photolithographic techniques are used to create the negative mold
silicon masters for use in replica molding. Three separate silicon masters are made
to fabricate three layers of the scaffold, which are then bonded together. These
photomasks are used to transfer feature patterns onto 100mm silicon wafers
patterned with SU-8 2000 series photoresist (Microchem) using a mask aligner
(Karl Suss). The height of the SU-8 layer is tunable simply by choice of the specific
SU-8 series product or the spin speed during SU-8 deposition on the wafers. The
mask aligner exposes the photosensitive resist to UV light through the mask. During
development of the resist, any areas exposed to UV light remain cross-linked to the
silicon surface, while unexposed areas are washed away. Lithographic masters are
postbaked and then passivated using a Teflon-like coating layer deposited in a
reactive ion etcher (STS).
3.2.3 Replica Molding and Soft Lithography using PDMS
3.2.3.1 PDMS Synthesis
PDMS is synthesized by mixing PDMS prepolymer and curing agent in a 10:1
ratio (Sylgard 184, Dow Corning). The mixture is evacuated for about 15 minutes or
until air bubbles are no longer present.
3.2.3.2 Replica Molding and Soft Lithography using PDMS
The PDMS is cast onto the silicon wafer in a petri dish in order to get a
workable mold and then evacuated for 15 minutes. It is cured at 65C for 2 hours,
and then the mold is removed. This step is shown in Figure 3-2. These PDMS (-)
molds are silane-coated overnight with 5 [d of silane. PDMS is then molded off of
these silane-coated PDMS molds to make PDMS (+) molds for use in PCL spin
casting. The PDMS (+) molds are replicas of the silicon wafers due to the double-
inverse replica molding.
I I I I
Silicon wafer
Silicon wafer
PDMS mold for cell migration
a. Synthesis of top layer (faces photoreceptor layer)
PDMS mold for cell cages
b. Synthesis of middle layer (encapsulates cells)
iIM-
Silicon wafer PDMS mold for nutrient delivery
c. Synthesis of bottom layer (faces pigment epithelium)
FIGURE 3-2: Schematic of the first step of double-inverse replica molding with
PDMS. This step generates the PDMS (-) molds that are then silane coated. This
process is repeated with the silane coated molds to generate PDMS (+) molds, which
are replicas of the silicon wafer.
3.2.4 PCL Thin Film Fabrication
3.2.4.1 Polycaprolactone Synthesis
A 10% solution of high molecular weight (80,000 MW) polycaprolactone is
dissolved in dichloromethane. The mixture is mixed for 3 hours at room
temperature.
I I I 1 111
:: i;i
:i
3.2.4.2 Polycaprolactone Spin Casting and Solvent Evaporation
The PDMS (+) molds are taped to silicon wafers with double-sided tape in
order to facilitate spin-casting. 5ml of 2% soap solution (Micro-90 Concentrated
Cleaning Solution, Cole-Parmer Instrument Company) is spun on the molds at 1500
RPM for 30 seconds to facilitate PCL release after spin-casting. 15ml PCL is poured
on the molds and let spread for 15-20 seconds. Then, as shown in Table 3-1, the
molds are spun at different speeds for 30 seconds depending on the mold's design in
order to optimize the formation of through-pores. They are spun open to air in
order to enhance solvent evaporation.
Table 3-1: Optimized Spin Speeds for PCL Spin-Casting
PDMS Mold Spin Speed (rpm)
Nutrient Pores 1500
Cell Cages 2200
Cell migration pores with ridges 2000
Then, the molds with spin cast PCL are placed in an oven at 700 C for 10 minutes to
melt the PCL. This is done to encourage the formation of through-pores and
enhancement of the design features by allowing PCL to infiltrate crevices of the
molds. The molds are spun again to facilitate drying at 1500 RPM for 20 seconds.
The PCL layers are then released from the molds either by submerging in water or
by peeling with tweezers. All PDMS molds are rinsed with water or methylene
chloride in between uses in order to remove any PCL still on the mold.
3.2.5 Pressure Bonding
Sections of each PCL thin film with through-pores, as evidenced by
examination of the films under microscope, are cut using biopsy punches. As shown
in Figure 3-3, the three unique layers of PCL are stacked in order from bottom to
top- nutrient pores, cell cages, cell migration pores- and aligned with the aid of 70%
ethanol to keep the sections from curling. The 3-D structure is held between glass
slides and pressure bonded under vacuum in a laminator at 400 C for 20 minutes. A
maximum of 3 scaffolds should be pressure bonded in the laminator at one time to
ensure a uniformly patent pressure bonding of all samples.
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FIGURE 3-3: Schematic of stacking, aligning, and bonding process.
Final scaffold is enlarged for clarity.
3.3 Results
3.3.1 Individual PCL Thin film Scaffolds
All images are captured using scanning electron microscopy (SEM). Samples
are cut and trimmed from thin film PCL scaffolds using a biopsy punch or razor
blade. They are sputter coated for 30 seconds at 30mA current using a Cressington
108auto Automatic Sputter Coater. They are then imaged using a Hitachi S-3500N
Scanning Electron Microscope.
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Using the methods described, all three layers have regions of through pores
shaped according to their respective designs. Figure 3-4 shows the relative size of
the features of each layer in order to depict the size of the cages for cell
encapsulation as well as the larger size of the cell migration pores as compared to
the nutrient infiltration pores.
FIGURE 3-4: The relative sizes of the features of the three PCL layers. Left: nutrient
pores, Middle: cell cages, Right: cell migration pores.
Figure 3-5 shows the thickness of the cell cages layer, which usually measures an
average of 12 pm. The three layers range in thickness from 8 pm to 13 pm according
to SEM measurements taken. Higher spin speeds yield a thinner PCL film. Usually,
PCL made from the synthesis procedure described above and spun at 1500 RPM for
30 seconds forms a thin film approximately 10 pm thin.
FIGURE 3-5: The thickness of the cell cages layer.
Figure 3-6 shows zoomed-in images of the nutrient pores and cell migration pores.
The nutrient pores exhibit relatively uniform circular geometry. The cell migration
pores clearly have hexagonally spaced ridges or grooves. However, these features
are less uniform than other mask designs. This is likely due to the more complicated
geometry and inability of PCL to fully mold around the shape of the posts.
FIGURE 3-6: A closer look at the smallest features of the scaffold.
Left: nutrient pore layer, Right: a cell migration pore with contact guidance ridges.
In Figure 3-7, the top of the PCL thin film that interfaces with the air during spin-
casting and the bottom that interfaces with the PDMS are shown. Clearly, the top
results in a peak thickness around the posts while the bottom has flat topography.
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FIGURE 3-7: Surface topography of both sides of the nutrient pore layer. Left: the
top side during the spin-casting process results in formation of a peak thickness
around the PDMS posts. Right: the bottom side that is against the PDMS during the
spin casting reveals a flat surface.
Figure 3-8 depicts the bendable nature of the polymer as well as the crystalline
lattices of PCL thin films. The bendable properties of the scaffold are optimal for this
r 
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retinal application because the device can better assume the landscape of the
subretinal space.
FIGURE 3-8: Texture and bendable properties of the PCL thin films. Left: The cell
cages scaffold shows the crystalline geometry of cured PCL. Right: The cell ridges
scaffold demonstrates the ability of PCL to deform and bend.
Table 3-2 summarizes the average diameter and standard deviations of design
features at sequential steps in the fabrication process: software designs,
transparency masks, SU-8 photolithography, and PCL spin-casting. Each value is an
average of five points (center, top, bottom, left, right) measured in a region
visualized to have through-pores under a microscope. Table 3-3 summarizes the
percent difference in feature diameter between the initial software design and the
final PCL thin film.
Table 3-2: Average Size of Design Features
L-Edit Software Transparency Silicon Wafer PCL thin
Design (pm) Mask (pm) (Ipm) film(pm)
Nutrient pores 10 10.1 ± .15 12.0 ± .34 11.8 ± .80
Cell Cages 216 217.5 ± .44 218.8 ± .90 213.4 ± 1.8
Cell migration
pores (including 72 73.0 ± .44 65.3 ± 1.0 62.7 ± 2.1
ridges)
Note: ± denotes standard deviation
Table 3-3: Percent Difference in Feature Diameter
Between PCL Scaffolds and L-Edit Software Design
% Difference
(PCL relative to
L-Edit design baseline)
Nutrient pores +18.0
Cell Cages -1.2
Cell migration
pores (including
ridges)
3.3.2 Three-Dimensional PCL Scaffold
The three individual layers are pressure bonded under vacuum to form a
patent 3-D thin film scaffolds. SEM images from various angles of the scaffold are
shown in figure 3-9. The top left image shows the edge of a stacked and bonded cage
scaffold with the nutrient pores facing upwards. The edges of the cell cages are
visible through the nutrient pore layer. In the top right image, which shows the
scaffold from the top, the edge of the cell cage, contact guidance pores, and nutrient
pores are all visible. The bottom left image shows a magnification of one cell cage of
the stacked and bonded scaffold with the contact guidance pores facing up. The
variations in the shape of the cell migration pores with contact guidance ridges are
visible in this view. Finally, the bottom right image shows the scaffold magnified on
one contact guidance pore, showing all three layers.
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FIGURE 3-9: Image of the 3-D scaffold after pressure bonding. Top left: view from
the back showing nutrient pores. Top right: View from the top of the scaffold.
Bottom left: View from the front of one cage. Bottom right: View from the front of
one cell migration pore.
3.4 Discussion
The fabrication process demonstrates that microstructured PCL thin films
can be successfully fabricated using photolithography and soft lithography
techniques. Furthermore, thin film scaffolds can be stacked and bonded to form 3-D
scaffolds with a unique architecture. The methods developed are effective at
fabricating the layers of the scaffold design and bonding them together to form
ultrathin devices approximately 30 gim thin.
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3.4.1 Precision of the Fabrication Process
The precision of the fabrication process from step to step can be gauged by
the diameter of design features. As summarized in Table 3-2, the diameter of the
features on all three layers varied after each step, as would be expected with
features at the micron scale. The features designed in L-Edit software are all
uniform in diameter. After conversion to transparency photomasks, all features
exhibit a slightly larger diameter on average: nutrient pores are 0.1 iim larger, the
cell cages are 1.5 iim larger, and the cell migration pores are 1 LIm larger. These
increases are attributable to the photoplotting software.
After the SU-8 photolithography process to convert transparency
photomasks to silicon wafers, the nutrient pores and cell cages are larger in
diameter by 1.9 [tm and 1.3 [m, respectively. This may be a result of the exposure of
a larger feature area of photosensitive resist to UV light through the mask than
would be predicted by the design on the transparency. This wider exposure at each
feature would crosslink a larger area to the silicon surface, resulting in a larger
feature size. On the other hand, the average diameter of the cell migration pore
decreases after this step by 7.7 jLm, a substantial fraction of the feature. This may be
a result of the more complicated geometry of the hexagonally ridged pore resulting
in less feature area of photosensitive resist being exposed to UV light through the
mask. This would result in a smaller feature size.
After soft lithography and double-inverse replica molding with PDMS, the
diameter of features in the PCL scaffolds are reduced on average by 0.2 pm for the
nutrient pores, 5.4 ktm for the cell cages, and 2.6 [tm for the contact guidance pores.
It is possible that when the PDMS (+) mold that is a replica of the silicon wafer is
being molded off of the PDMS (-) mold, the PDMS does not infiltrate the crevices of
the PDMS (-) mold to the greatest extent possible. This may be a result of the silane
coating on the PDMS (-) mold.
These acute variations in diameter are expected when working with such
precise features at the micron scale. The variations are more significant for the
smaller features because they are distorted by a larger percent of their original area,
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depending on the magnitude of the variation. As summarized in Table 3-3, the
percent difference in feature diameter between the original L-Edit design and the
PCL scaffold is greatest for the smallest features, the nutrient pore layer. The next
largest percent difference is for the next smallest feature, the cell migration pores.
The design with the least percent difference between the L-Edit template and the
PCL thin film is the cell cages, due to its larger design.
Furthermore, at every step, the standard deviation increased for all three
layers. This increase in amount of feature variability is due to the fact that the
process became increasingly user and materials dependent. The process becomes
less precision-controlled by software and micromachining, resulting in greater
variation. In addition, the cell migration pore with hexagonally ridged geometry
exhibited the greatest standard deviations throughout the process. Again, this is
likely attributable to the more complicated geometry of the design as compared to
simple circle pores on the other two designs. The hexagonal ridges are capable of
bending, twisting, and stretching, thereby increasing variation.
3.4.2 Reproducibility of the Process
The fabrication process is controlled and reproducible for future
applications. However, the step with the greatest variation is the PCL spin-casting
and solvent evaporation. Though every iteration for each layer of the scaffold yields
regions of the PCL thin film with through-pores, the area of these regions varies.
This variation determines the size of the 3-D scaffold that it is possible to fabricate.
The most common size scaffold to fabricate is 5mm x 5mm because of readily
available regions of this size with through-pores on each scaffold layer. Larger
scaffolds such as 12mm x 12mm are possible but are fabricated less frequently,
limited most often by the formation of through-pores on the cell migration pores
layer. As a result of the more complex geometry of this design, there is greater
variability of through-pore regions on this PCL thin film. The nutrient pores and cell
cages are highly consistent in their outcome of a large area of through-pores in the
PCL thin film.
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Chapter 4: In Vitro Testing
4.1 Introduction
Medical devices are first tested in a controlled environment outside of
organisms and animals in order to ensure that it will function as it is designed to.
Devices made from biomedical engineering techniques are tested in an environment
that simulates that of humans but does not have complications that may arise in
humans. Thus, it is a first pass study to discern basic functionality of the device
without the variables that traditionally arise in animals. The in vitro
experimentation of this microfabricated 3-D stem cell delivery scaffold will include
seeding of the scaffolds with retinal progenitor cells (RPCs), evaluation of cell
localization and migration in the scaffold, and an assessment of cell population in
the cages designed for cell encapsulation.
4.2 Materials and Methods
4.2.1 Retinal Progenitor Cells
Cell type, scaffold material, and growth factors must be properly selected in
order to best allow the cells to integrate in the host tissue and differentiate into
photoreceptor cells. Previous research has shown that differentiated tissue is not
able to integrate properly into host retinal tissue.30 In addition, neural progenitor
cells do not completely differentiate into the desired retinal cells.31 Research has
shown that retinal progenitor cells (RPCs) would be an effective cell type for retinal
tissue engineering. They have shown an ability to integrate into the layers of the
retina and are able to undergo complete differentiation into retinal neurons. 32 As
shown in Figure 4-1, RPCs form clusters of cells called neurospheres with increased
cell growth and proliferation in suspension. In addition, RPCs are an
immunopriveleged cell type and will not elicit an immunogenic response when
injected into a subretinal space.33 RPCs are therefore an efficacious cell type to
employ in this project.
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FIGURE 4-1: Formation of RPC neurospheres with increasing
cell growth and proliferation in suspension.
4.2.2 Cell Seeding
Four 5mm x 5mm circular PCL scaffolds are prepared for cell seeding. The
scaffolds are placed in a 24-well plate and sterilized in UV light for 55 minutes. The
scaffolds are further sterilized by submersion in 70% ethanol for 2 hours 25
minutes. The scaffolds are rinsed 4 x 15 minutes in HBSS. They are then submerged
in NB complete media at 370 C overnight.
Retinal progenitor cells are isolated and cultured at Schepens Eye Research
Institute, Boston, Massachusetts. 1ml of cells at 4x10 5 cells/ml are spun down in a
centrifuge at 1000 RPM for 7 minutes. The media is aspirated, and the pellet is
resuspended in 500[jl NB complete media as a wash step. The suspension is spun
again at 1000 RPM for 6 minutes. The media is aspirated, and the pellet is
resuspended in 40[tl to make 1x10 7 cells/ml.
Two scaffolds are placed in a 96-well plate; their orientation was checked
under a microscope to ensure the cell migration pores were facing up. 5 [l of cell
suspension is pipetted onto the scaffolds. The 96-well plate is placed in a vacuum
desiccator. A weight is placed on the lid to prevent it from lifting off when the
vacuum is pulled. Vacuum is pulled 6 times for 30 seconds each time at 4 in.Hg,
releasing to atmosphere between each cycle, according to prior literature. 34 The
other two scaffolds are placed in the 96-well plate. They are directly seeded without
vacuum backfill by pipetting 5ild cells directly on top of the scaffolds. The scaffolds
are incubated for 45 minutes at 37 0 C before collecting Day 0 images by fluorescent
microscopy. Then 60il of media is added to each well and incubated overnight. 24
hours later, 501 of media is added to each well. On days 3, 5, and 7, the majority of
the media is pipetted out to flatten the scaffold and facilitate imaging. After imaging,
100 1 media is added to each well and returned to the incubator at 370 C for another
48 hours.
The fluorescent microscopy images are analyzed using ImageJ software made
available by the NIH. Images from Day 0, 3, 5 and 7 of the four experimental
scaffolds are analyzed. It is assumed that any area of fluorescence indicates cell
presence at that location. Therefore, fluorescence is an indicator of cell survival,
proliferation, and localization. The area of RPCs GFP fluorescence in individual cell
cages was measured cage-by-cage using the ImageJ area measurement software.
Using the shape tools, the region of fluorescence of each cell or group of cells is
defined by the user, and the software calculates the area of that region. An example
of this method is shown in Figure 4-2.
FIGURE 4-2: Selection of areas of cell fluorescence in ImageJ. The area of
fluorescence in each cage is an indicator of cell presence, survival, and proliferation.
Only cages that were both in focus and included the entire area of the cage
were included for analysis. In addition, only cells inside the cages or at the border of
the cages were counted. The area of fluorescence was converted to 'percent area of
the cell cage covered by cells' by a simple calculation, using the approximate area of
each cage as 3.53 x 104 jm 2. There was variability of the number of cages measured
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for each sample at each time point. To keep the sample size the same and include
cages with pertinent cell presence, the ten highest values of 'percentage area of cell
cage covered by cells' for each scaffold at each time point were averaged.
4.3 Results
4.3.1 Retinal Progenitor Cell Localization
On day 7 after cell seeding, scaffolds are stained with 4 pM Ethidium solution
(Invitrogen) for 30 minutes at room temperature and covered by foil. They are
imaged using fluorescent microscopy with a rhodamine filter. This provides
information about cell localization and efficacy of the standard cell seeding, Figure
4-3, versus the vacuum backfill seeding technique, Figure 4-4.
FIGURE 4-3: Ethidium staining on day 7 of the standard cell seeding scaffolds. It
shows a random distribution of RPCs in relation to the scaffold features. Left: bright
field image showing scaffold structure, Right: fluorescent image showing cell
localization in relation to scaffold structure.
FIGURE 4-4: Ethidium staining on day 7 of the vacuum backfilled scaffold. It shows
preferential localization of RPCs to the cages. Left: bright field image showing
scaffold structure, Right: fluorescent image showing cell localization in relation to
scaffold structure.
4.3.2 Confocal Microscopy
As shown in Figures 4-5 and 4-6, images taken by confocal microscopy on
day 7 after cell seeding shed further insight on cell localization in the Z-direction. It
is important to verify that cells are in fact in the middle layer of the scaffold in the
cell cages and not merely seeded on top of the scaffold over the cell cages.
FIGURE 4-5: Confocal images of standard cell seeded scaffolds on day 7. The
orthogonal view reveals that the cell at the intersection of the x- and y- crosshairs is
in the middle of the z-stack. Over the time course, the cells were able to adhere to
the scaffold and migrate into the cages.
FIGURE 4-6: Confocal images of vacuum backfilled scaffolds on day 7 after seeding.
The orthogonal view reveals that the cell at the intersection of the x- and y-
crosshairs is in the middle of the z-stack.
From fluorescent microscopy images, RPCs appeared to localize to regions of the cell
cages over time, but the confocal images confirm that the cells are centrally located
in the middle of the scaffold thickness. The green color in the confocal images
surrounding the cell cages is merely reflection off of the PCL polymer or media
during confocal imaging and not the presence of cells.
4.4.3 Cell Population in Cell Cages
As described above, the cell population in the cell cages is measured by
calculating the area of RPC-GFP fluorescence in individual cages with ImageJ
software. The graph in Figure 4-7 is generated using the average data of the two
vacuum backfilled scaffolds and the average data of the two standard seeded
scaffolds. The vacuum backfilled sample has a higher initial cell population in the
cages. However, the RPC population in these scaffolds begins to fall off sooner than
the population in the standard seeded scaffolds.
Measurement of Cell Population in Cell Cages
by % Area of RPC-GFP Fluorescence
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FIGURE 4-7: Measurement of cell population in cell cages
by % area of cell fluorescence over a 7 day time course.
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4.4 Discussion
4.4.1 Scaffold Integrity during Cell Culture
As demonstrated in previous literature, these in vitro experiments confirmed
that PCL is a polymer compatible with RPC applications. The RPCs can be cultured in
the scaffold, and they would be able to achieve greater cell densities with delivery of
optimal therapeutics. Furthermore, the imaging showed that the scaffold is patent
throughout the 7 day time course in the experiment. The individual layers do not
come apart or disintegrate over the period of the cell culture. The pressure bonding
technique used to bond the layers is clearly sufficient for this application. The 3-D
scaffold is an effective device to encapsulate and culture cells.
4.4.2 Cell Localization and Migration
As revealed by GFP fluorescence in images captured by fluorescent and
confocal microscopy, the cells are able to localize to the cages designed for cell
encapsulation. However, the vacuum backfill seeding technique results in greater
localization in the cages, while the standard cell seeding technique results in a more
random distribution of cells. Seeding technique is important to consider given that
the goal of the procedure is to optimize cell encapsulation specifically inside the
cages. In Figure 4-4, a scaffold that was seeded using vacuum backfilling, the
majority of cells appear to be contained specifically in the cages. On the other hand,
in Figure 4-3, a scaffold that was seeded using standard techniques, the cells appear
to more randomly distributed and less localized selectively to the cages. There
appear to be cells in between cages, perhaps on top of the scaffold.
Confocal microscopy is necessary to ensure that the cells actually localize
inside the cages and not simply on top. Using stacks in the Z-direction, the specific
location within the 3-D scaffold can be determined. As shown in Figure 4-6, scaffolds
seeded by vacuum backfilling, alignment of the crosshairs on a specific cell shows
the location of the cell in the z-stack in the orthogonal view. In both examples, the
cells are in the center of the scaffold in the z-direction. This is the location of the
centrally located cages for cell encapsulation. In Figure 4-5, scaffolds seeded by
standard techniques, cells are also centrally located in the z-direction, indicating
their containment inside the cages. These cells were able to migrate through the
hexagonally ridged pores and into the cages over the 7 day time course. This is also
a strong indication of the migration ability of RPCs through the hexagonally ridged
pores with built-in contact guidance cues. In order for the cells to travel from the top
of the scaffold after standard cell seeding to the inside of the cages, they must have
had to adhere and migrate. This indicates that the hexagonal ridges pores will
effectively allow for cell migration out of the scaffold into the subretinal space after
transplantation.
4.4.3 Cell Survival
The measurement of cell population in the cell cages by average percent area
of the cell cage covered by fluorescence sheds light on cell survival and proliferation
over the 7 day time course. It also allows for a comparison of the vacuum backfill
seeding technique to the standard cell seeding technique. According to Figure 4-7,
the vacuum backfilled scaffolds have more than twice the initial cell population in
the cages than the standard cell seeded scaffolds. This reaffirms the findings in the
fluorescent microscopy images that the vacuum backfill technique leads to more
selective RPC localization to the inside of the cages. Furthermore, the vacuum filled
scaffolds have higher cell populations for the duration of the time course. To
increase the RPC population in the cages and reduce the number of seeded cells that
are not ultimately encapsulated by the cages, the vacuum backfill technique is likely
the stronger the choice.
Both scaffold types exhibited steady rises in the presence of cells in the cages,
but the duration of this rise differed. For the vacuum backfilled scaffolds, the cell
population increased for the first five days but was tapering off by day 7. On the
other hand, the cell population in the standard seeded scaffolds continued to
increase over the 7 day time course. According to this data, even though the vacuum
seeded scaffolds have higher initial cell populations in the cages, the cell viability
falls off sooner than the standard seeded scaffolds. This may be a result of the
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vacuum backfilling process. It is possible that the technique exerts forces on the
RPCs that reduce their survival chances even as they localize to the cages. Though
the standard seeded scaffolds have a lower initial cell population, they exhibited
continued proliferation over the 7 day time course.
These results deem it difficult to conclusively determine the duration of cell
viability in these scaffolds or the cell seeding technique that allows for greater cell
viability, if any. Further studies with a larger number of scaffolds and sacrificial
scaffolds for testing at individual time points is needed for more definitive results
about cell survival and proliferation. However, it does show promise that all
scaffolds showed an early boost in cell population, despite the varied duration of the
boost. Further studies should be geared towards optimizing and lengthening the
duration of the cell proliferation period.
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Chapter 5: Conclusion
5.1 Overview of Current Progress
There is a need for improved treatment options for retinal diseases such as
AMD and RP that degenerate photoreceptor cells and ultimately leads to blindness.
The goal of this thesis project was to engineer a scaffold for retinal progenitor cell
grafting using standard microfrabrication techniques. The specific aims are to
design the scaffold architecture, fabricate it using photolithography, soft
lithography, and replica molding techniques, and evaluate the scaffold in vitro using
retinal progenitor cells. The scaffold offers several advantages that previously
designed scaffolds for retinal progenitor cell grafting do not offer. It is able to deliver
a large number of cells without the possibility of the cells being sheared off. It allows
for unidirectional migration of cells out of the scaffold and into the subretinal space.
It is ultrathin and open to the retina on both sides, allowing for nutrient infiltration.
The scaffold can serve as an organized framework to support cell migration and
integration, a matrix to promote cell adhesion, a barrier to prevent infiltration of
surrounding tissue, a reinforcement of the retinal tissue structure, and even a
delivery vehicle for growth factors.
This cell-scaffold composite will allow for controlled, precise, localized
delivery of cells to the subretinal space to restore retinal tissue damaged by disease
or trauma. Using precisely tuned structural, chemical, and physiological cues, retinal
regenerative therapy and differentiation of a large number of photoreceptors for
clinical use is distinctly possible. The culture of retinal progenitor cells in an
environment that resembles the native retina can lead to redevelopment of
degenerated retinal tissue. Due to the small size-scale of the retina and the need for
fine-tuning of device features, microfabrication techniques are effective for retinal
applications. With the aid of these techniques, the individual layers of the scaffold
are patently bonded and the 3-D stem cell delivery scaffold for retinal regenerative
therapy is fabricated. Furthermore, in vitro experimentation confirms that RPCs can
be cultured and delivered using this device.
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5.2 Future Directions
Future in vitro testing includes experimentation with large numbers of 3-D
scaffolds to allow for sacrifice of scaffolds at various time points. This will provide
further insight into RPC viability and proliferation over a time course. The sacrifice
of scaffolds will allow for use of diagnostics such as flow cytometry, plate reading,
incremental live/dead assays, and various other staining techniques. Another step
in the in vitro studies will include immunohistochemistry to determine expression
of mature cell markers and provide an assessment of differentiation.
The device itself can be modified into a drug delivery vehicle. Incorporation
of therapeutics by absorption, embedding, encapsulation, nanoparticle
incorporation, or hydrogel delivery are all possibilities. These therapeutic molecules
can initiate differentiation of the transplanted cells prior to migration into the
neuroretina. Depending on which layer of the device is modified, therapeutics can
be delivered to either the transplanted cells in the cages, the retinal pigment
epithelium, or the photoreceptors in the neuroretina. Therapeutics delivered to the
transplanted cells could enhance survival and differentiation. Molecules delivered to
the retinal pigment epithelium could encourage angiogenesis. Therapeutics to the
photoreceptors could help protect them from further degeneration associated with
AMD or RP or from damage due to the implanted device.
Due to the physical inactivity and relative stability of the retina, mechanical
testing is not crucial. However, testing can be done to determine whether pressure
bonding, bonding via plasma treatment, chemical bonding, or thermal bonding
enhances device strength. It would also be interesting to determine how PCL
properties or the scaffold's architecture can be altered to best mimic the native
retina.
In the in vitro studies, cell seeding was conducted via vacuum backfilling or
conventional seeding techniques. Another approach to assess is cell encapsulation
with a secondary gel matrix. The gel can provide an environment for the cells that is
most conducive to neural differentiation irrespective of the material properties.
Furthermore, the device design itself can be extended to other biodegradable
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polymers, such as poly(glycerol sebacate) (PGS). The device can be made using
other methods of fabrication such as sacrificial molding, injection molding, material
printing, and laser machining.
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